Results 51 to 60 of about 35,525 (153)

Metabolic effects of sodium-glucose co-transporter 2 inhibitor

Клінічна ендокринологія та ендокринна хірургія, 2022
The literature review considers the new universal molecule empagliflozin, which managed to change the glucose‑centric approach in endocrinology to an organoprotective one. The results of the pivotal clinical trials conducted with empagliflozin (EMPA‑REG‑OUTCOME, EMPEROR‑REDUCED, EMPEROR‑PRESERVED and EMPULSE) strongly support the ability of ...
openaire   +3 more sources

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches

Frontiers in Pharmacology, 2023
Sodium-glucose co-transporter type 2 (SGLT 2, gliflozins) inhibitors are potent orally active drugs approved for managing type 2 diabetes. SGLT 2 inhibitors exert a glucose-lowering effect by suppressing sodium-glucose co-transporters 1 and 2 in the ...
Yu Zhang, Panpan Xie, Yamei Li, Zhixing Chen, Aixin Shi   +4 more
doaj   +1 more source

ASSESSMENT OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR IN COMBINATION WITH INSULIN ON METABOLIC PARAMETERS AND RENAL MORPHOFUNCTIONAL CHANGES IN RATS WITH EXPERIMENTAL DIABETES MELLITUS

Juvenis Scientia, 2017
Sodium-glucose co-transporter type 2 inhibitors belong to modern class of oral hypoglycemic drugs, exerting its effect through the reduction of renal glucose reabsorption.
D. A. Lebedev, N. P. Likhonosov, Т. P. Tuchina, V. K. Bayrasheva, A. Yu. Babenko   +4 more
doaj  

"Histological and Immunohistochemical Study of the Protective Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors on Streptozotocin Induced Pancreatic Damage In Adult Male Albino Rats" [PDF]

Minia Journal of Medical Research
Background: SGLT2 inhibitor is a type of medication prescribed for treatment of type 2 diabetes. By prevention the reabsorption of glucose in the kidneys, these drugs facilitate glucose removal through urine.Aim: Investigate protective effect SGLT2 ...
Abdel Hamid AboBakr, Mohamed Desouky, youssra Hassan, Medhat Ata   +3 more
doaj   +1 more source

Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis.

PLoS ONE
Several new classes of medications for diabetes have recently become available newer medication classes have been increasing in use. It is unclear how their utilization varied across provinces and how the COVID-19 pandemic may have affected these trends.
Jessica Riad, Fred Abdelmalek, Noah Ivers, Mina Tadrous   +3 more
doaj   +1 more source

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Cardiovascular Diabetology, 2019
Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of glucose
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari   +7 more
doaj   +1 more source

Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control

Indian Journal of Endocrinology and Metabolism, 2019
Type 2 diabetes mellitus (T2DM) is a family of metabolic disorders characterized by hyperglycemia as a consequence of abnormalities in insulin secretion and insulin sensitivity. It affects hundreds of millions of people worldwide and leads to increased morbidity, compromised quality of life, higher mortality sodium glucose co-transporter 2 (SGLT2 ...
Manash Pratim Baruah, B M Makkar, Vikrant B Ghatnatti, Kaushik Mandal   +3 more
openaire   +3 more sources

Incidental diagnosis of euglycaemic diabetic ketoacidosis: a case report

Journal of the Pakistan Medical Association
Euglycaemic diabetic ketoacidosis (eu-DKA) is a rare but serious complication of sodium-glucose co-transporter 2 (SGLT2) inhibitors, characterized by metabolic acidosis, elevated ketones and may be overlooked because of the absence of marked ...
Abrar Ali, Salva Shariq, Ramsha Abid, Muhammad Qamar Masood   +3 more
doaj   +1 more source

Sodium–glucose co-transporter 2 inhibitors in heart failure

European Heart Journal - Cardiovascular Pharmacotherapy, 2021
Giuseppe M C Rosano, Cristiana Vitale, Gianluigi Savarese   +2 more
openaire   +2 more sources

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

, 2020
peer ...
Mifsud, Simon, Schembri, Emma Louise, Montebello, Annalisa, Gruppetta, Mark   +3 more
openaire   +1 more source